Biogen
Institution Profile
Recognized for Excellence As a Med Honors Top Pharmaceutical Innovator, Biogen stands at the forefront of neuroscience research and drug development. Founded in 1978, Biogen has pioneered treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease. The company's MS portfolio includes disease-modifying therapies that have transformed patient outcomes. Biogen's breakthrough in Alzheimer's treatment with lecanemab (Leqembi) represents a significant advancement in addressing the cognitive decline associated with the disease. Additionally, Biogen's commitment to rare diseases is exemplified by its development of nusinersen (Spinraza) for SMA, offering hope to patients with this devastating condition. Beyond neurology, Biogen is expanding into biosimilars and exploring treatments for neuropsychiatric conditions. Through relentless research and development, Biogen continues to push the boundaries of medicine, offering new hope to patients with complex neurological conditions worldwide.
Profile last updated: July 9, 2026
2026 TOP PHARMACEUTICAL INNOVATORS
Biogen
Also Featured

